SODIUM ESTRADIOL

First approved in 1940

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H23O2.Na
Molecular Weight	294.3638
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]3([H])C4=C(CC[C@@]23[H])C=C([O-])C=C4

InChI

InChIKey=NHTBIADYQKCUHK-CMZLOHJFSA-M

InChI=1S/C18H24O2.Na/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20;/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3;/q;+1/p-1/t14-,15-,16+,17+,18+;/m1./s1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C18H24O2
Molecular Weight	272.382
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11250930https://pubchem.ncbi.nlm.nih.gov/compound/222757http://www.drugbank.ca/drugs/DB00783
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020375s027lbl.pdf

Estradiol an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. In humans, it is produced primarily by the cyclic ovaries and the placenta. It is also produced by the adipose tissue of men and postmenopausal women. The 17-alpha-isomer of estradiol binds weakly to estrogen receptors (receptors, estrogen) and exhibits little estrogenic activity in estrogen-responsive tissues. Estradiol enters target cells freely (e.g., female organs, breasts, hypothalamus, pituitary) and interacts with a target cell receptor. When the estrogen receptor has bound its ligand it can enter the nucleus of the target cell, and regulate gene transcription which leads to formation of messenger RNA. The mRNA interacts with ribosomes to produce specific proteins that express the effect of estradiol upon the target cell. Estradiol is used for the treatment of urogenital symptoms associated with post-menopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria). Estradiol is marketed under the brand name Climara (among others), indicated for: the treatment of moderate to severe vasomotor symptoms due to menopause, treatment of symptoms of vulvar and vaginal atrophy due to menopause, treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure and prevention of postmenopausal osteoporosis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Steryl-sulfatase 33 Target ID: P08842 Gene ID: 412.0 Gene Symbol: STS Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11250930	Substrate 661
Estrogen receptor alpha 127 Target ID: CHEMBL206 Sources: http://www.drugbank.ca/drugs/DB00783	Agonist 2678	0.0084 nM [EC50]
Estrogen receptor beta 110 Target ID: CHEMBL242 Sources: http://www.drugbank.ca/drugs/DB00783	Agonist 2678	1.4 nM [EC50]
Androgen Receptor 167 Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16309907	Antagonist 2778	19.1 nM [IC50]
Estrogen receptor alpha 127 Target ID: CHEMBL206 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/222757	Agonist 2678	0.13 nM [Ki]
Estrogen receptor beta 110 Target ID: CHEMBL242 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/222757	Agonist 2678	0.09 nM [Kd]

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Vaginal atrophy 27 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020375s027lbl.pdf	Primary	Approved 8429	CLIMARA Approved Use Climara is an estrogen indicated for: •Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause •Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause •Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure •Prevention of Postmenopausal Osteoporosis Launch Date 1974
Postmenopausal osteoporosis 59 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020375s027lbl.pdf	Preventing	Approved 8429	CLIMARA Approved Use Climara is an estrogen indicated for: •Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause •Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause •Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure •Prevention of Postmenopausal Osteoporosis Launch Date 1974
Primary ovarian failure 27 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020375s027lbl.pdf	Primary	Approved 8429	CLIMARA Approved Use Climara is an estrogen indicated for: •Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause •Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause •Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure •Prevention of Postmenopausal Osteoporosis Launch Date 1974
Unknown 2578

C_max

Value	Dose	Co-administered	Analyte	Population
14.7 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022038s005s006lbl.pdf	0.25 mg 1 times / day steady-state, topical dose: 0.25 mg route of administration: Topical experiment type: STEADY-STATE co-administered:		ESTRADIOL plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN
92 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020655s020lbl.pdf	0.05 mg 1 times / day multiple, topical dose: 0.05 mg route of administration: Topical experiment type: MULTIPLE co-administered:		ESTRADIOL plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
236 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022038s005s006lbl.pdf	0.25 mg 1 times / day steady-state, topical dose: 0.25 mg route of administration: Topical experiment type: STEADY-STATE co-administered:		ESTRADIOL plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
10 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022038s005s006lbl.pdf	0.25 mg 1 times / day steady-state, topical dose: 0.25 mg route of administration: Topical experiment type: STEADY-STATE co-administered:		ESTRADIOL plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN
1.75 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020655s020lbl.pdf	0.05 mg 1 times / day multiple, topical dose: 0.05 mg route of administration: Topical experiment type: MULTIPLE co-administered:		ESTRADIOL plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737	substrate 1037	substrate 1217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP1B1 92 CYP1A1 349 CYP1A2 1054 CYP3A5 395 CYP3A7 110 CYP2C18 138 CYP2E1 667 CYP2A6 543 CYP2B6 664 CYP2C8 693 CYP2C19 991 UGT1A1 418 UGT1A3 422 UGT1A4 347 UGT1A5 55 UGT1A6 307 UGT1A7 236 UGT1A8 283 UGT1A9 380 UGT1A10 291 UGT2A2 48 UGT2A3 48 UGT2B4 249 UGT2B7 389 UGT2B10 127 UGT2B17 213 UGT2B28 63	CYP2B6 547

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2B6 1001	inducer 1573 Sources: https://www.sciencedirect.com/science/article/pii/S0006295212002328 Page: -	yes
P-gp 1650	supressor 155 Sources: https://pubs.acs.org/doi/abs/10.1021/mp900077q Page: -	yes

Drug as victim

Target	Modality	Activity
CYP2A6 543	substrate 3367 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	minor
CYP2B6 664	substrate 3367 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	minor
CYP2C19 991	substrate 3367 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	minor
CYP2C8 693	substrate 3367 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	minor
CYP2C9 1037	substrate 3367 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	minor
CYP2D6 1217	substrate 3367 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	minor
CYP2C18 138	substrate 3367 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	no
CYP2E1 667	substrate 3367 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	no
UGT1A5 55	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	no
UGT1A6 307	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	no
UGT1A7 236	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	no
UGT1A9 380	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	no
UGT2B10 127	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	no
UGT2B28 63	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	no
UGT2B4 249	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	no
UGT1A1 418	substrate 3367 Sources: https://dmd.aspetjournals.org/content/30/11/1266.short Page: -	yes [Km 7 uM]
CYP1A1 349	substrate 3367 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	yes
CYP1A2 1054	substrate 3367 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	yes
CYP1B1 92	substrate 3367 Sources: https://www.pnas.org/content/93/18/9776.short Page: -	yes
CYP3A4 1737	substrate 3367 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	yes
CYP3A5 395	substrate 3367 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	yes
CYP3A7 110	substrate 3367 Sources: https://academic.oup.com/endo/article/146/7/2911/2499912 Page: -	yes
UGT1A10 291	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	yes
UGT1A3 422	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	yes
UGT1A4 347	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	yes
UGT1A8 283	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	yes
UGT2A2 48	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	yes
UGT2A3 48	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	yes
UGT2B17 213	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	yes
UGT2B7 389	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234363/ Page: -	yes

Sourcing

Vendor/Aggregator	ID	URL
AEchem Scientific Corp., USA	AE046017	http://www.aechemsc.com/info_products/AE046017.php
AHH Chemical co.,ltd	API-1858	http://www.ahhchemical.com/product/API-1858.html
AHH Chemical co.,ltd	NP-1226	http://www.ahhchemical.com/product/NP-1226.html
AK Scientific, Inc. (AKSCI)	H061	http://www.aksci.com/item_detail.php?cat=H061
AK Scientific, Inc. (AKSCI)	J10189	http://www.aksci.com/item_detail.php?cat=J10189
Aaron Chemicals	AR0035II	http://www.aaronchem.com/50-28-2
AbMole Bioscience	M5625	http://www.abmole.com/products/estradiol.html
Achemtek	0104-010473	http://www.achemtek.com/50-28-2
Acorn PharmaTech	ACN-032013	http://www.acornpharmatech.com/
Acros Organics	AC436320250	https://www.fishersci.com/shop/products/estradiol-98-acros-organics-1/AC436320250
Acros Organics	AC436320050	https://www.fishersci.com/shop/products/estradiol-98-acros-organics/AC436320050
Alfa Aesar	L03801	https://www.alfa.com/en/catalog/L03801/
Alsachim	1651	http://www.alsachim.com/product-C2920-glo.bal-view.html
ApexBio Technology	A8425	http://www.apexbt.com/estradiol-22654.html
Aurora Fine Chemicals LLC	A13.142.520	http://online.aurorafinechemicals.com/info?ID=A13.142.520
Aurum Pharmatech LLC	Z-4415	http://www.Aurumpharmatech.com/Product/ProductDetails/Z_4415
AvaChem Scientific	4548	http://www.avachem.com/productSearch.asp?4548
Avantor Inc	101094-946	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101094-946
BioChemPartner	BCP08579	http://www.biochempartner.com/50-28-2-BCP08579
BioSynth	Q-201503	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-201503.html
Boerchem	BC200811	http://www.boerchem.com/?product_33552.html
Calbiochem	3301	http://www.emdbiosciences.com/product/3301
Chem Scene	CS-1938	http://www.chemscene.com/50-28-2.html
ChemFaces	CFN90035	http://www.chemfaces.com/natural/Estradiol-CFN90035.html
ChemMol	1203050	http://www.chemmol.com/chemmol/1203050.html
ChemMol	2101440	http://www.chemmol.com/chemmol/2101440.html
ChemMol	2101445	http://www.chemmol.com/chemmol/2101445.html
ChemMol	30100431	http://www.chemmol.com/chemmol/30100431.html
ChemMol	44000538	http://www.chemmol.com/chemmol/44000538.html
Chemenu	CM110581	http://www.chemenu.com/products/CM110581
Chemspace	CSSB00000693940	https://chem-space.com/CSSB00000693940
Clearsynth	CS-O-11584	https://www.clearsynth.com/en/CSO11584.html
DC Chemicals	DCAPI1200	http://www.dcchemicals.com//product_show-Estradiol.html
EMD Millipore	3301	http://www.emdbiosciences.com/product/3301
Enamine	Z1847670481	https://www.enaminestore.com/catalog/Z1847670481
Glentham Life Sciences	GP9683	http://www.glentham.com/products/product/GP9683/
LGC Standards	DRE-C13213100	https://www.lgcstandards.com/US/en/p/DRE-C13213100
LGC Standards	DRE-XA13213100AL	https://www.lgcstandards.com/US/en/p/DRE-XA13213100AL
Lab Network	LN00235694	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00235694
Matrix Scientific	194601	https://www.matrixscientific.com/194601.html
MedChem Express	HY-B0141	https://www.medchemexpress.com/Estradiol.html
MuseChem	I013886	https://www.musechem.com/product/I013886.html
MuseChem	M131188	https://www.musechem.com/product/M131188.html
OChem	2711	http://www.ocheminc.com/index.php?act=psearch&pid=003E693
Parchem	18436	http://www.parchem.com/chemical-supplier-distributor/Estradiol-complex-008436.aspx
Sigma-Aldrich	E-060_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/e060?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	E1024_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/e1024?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	E1132_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/e1132?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	E125_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/e125?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1250008_USP	https://www.sigmaaldrich.com/catalog/product/usp/1250008?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S772629	https://www.smolecule.com/products/s772629
THE BioTek	bt-267766	https://www.thebiotek.com/product/inhibitors/bt-267766
Tocris	2824	https://www.tocris.com/products/b-estradiol_2824
VladaChem	VL268274-1G	https://www.vladachem.com/product.php?products=50-28-2
Yuhao Chemical	LT1224	http://www.chemyuhao.com/50-28-2.html
eNovation Chemicals	D382843	http://www.enovationchem.com/productDetails.asp?productID=D382843
eNovation Chemicals	D961664	https://www.enovationchem.com/ProductDetails.asp?ProductID=D961664
iChemical	EBD2157872	http://www.ichemical.com/products/50-28-2.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
Effect of estradiol benzoate on the proliferation of osteogenic cells in fetal rat fibulae cultured in vitro.	1978 Mar	674716
Sulfation of estrone and 17 beta-estradiol in human liver. Catalysis by thermostable phenol sulfotransferase and by dehydroepiandrosterone sulfotransferase.	1992 May-Jun	1355717
[The effect of adrenaline and 17beta-estradiol sulfate on transmembrane potentials of guinea pig cardiomyocytes].	1996 Dec	9280454
Suppressive effects of estradiol on 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated transcriptional activation of murine Cyp1a-1 in mouse hepatoma Hepa 1c1c7 cells.	1998 Nov 27	10072167
Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta.	1998 Oct	9751507
Differential regulation of c-fos expression in estrogen-induced hamster renal tumors compared with kidney not due to creation of an estrogen-response element by point mutation in the gene's flanking sequence.	1999 Apr	10326862
Estrogenicity of bisphenol A in a human endometrial carcinoma cell line.	1999 Apr 25	10411312
Estrogen and aryl hydrocarbon responsiveness of ECC-1 endometrial cancer cells.	1999 Apr 25	10411295
Growth stimulation of a rat pituitary cell line MtT/E-2 by environmental estrogens in vitro and in vivo.	1999 Aug	10580743
Lack of mutations in DNA polymerase beta of estradiol-induced hamster kidney tumors: sequence of hamster DNA polymerase beta cDNA.	1999 Aug	10402247
Inhibitory effect of natural and environmental estrogens on thymic hormone production in thymus epithelial cell culture.	1999 Dec	10606005
Estrogen-induced pituitary tumor development in the ACI rat not inhibited by dietary energy restriction.	1999 Dec	10569801
Rapid inhibition of rat brain mitochondrial proton F0F1-ATPase activity by estrogens: comparison with Na+, K+ -ATPase of porcine cortex.	1999 Feb 26	10096774
Low-dose bioactivity of xenoestrogens in animals: fetal exposure to low doses of methoxychlor and other xenoestrogens increases adult prostate size in mice.	1999 Jan-Mar	10188188
[Physiology and exploration of the gonadotropic axis].	1999 Jun 15	10488657
Estrogenic potential of certain pyrethroid compounds in the MCF-7 human breast carcinoma cell line.	1999 Mar	10064545
Effects of environmental estrogens on tumor necrosis factor alpha-mediated apoptosis in MCF-7 cells.	1999 Nov	10545406
Estrogen directly respresses gonadotropin-releasing hormone (GnRH) gene expression in estrogen receptor-alpha (ERalpha)- and ERbeta-expressing GT1-7 GnRH neurons.	1999 Nov	10537130
The aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT) heterodimer interacts with naturally occurring estrogen response elements.	1999 Nov 25	10619402
Perinatal exposure to estrogenic compounds and the subsequent effects on the prostate of the adult rat: evaluation of inflammation in the ventral and lateral lobes.	1999 Nov-Dec	10613394
Circadian expression of the steroid 15 alpha-hydroxylase (Cyp2a4) and coumarin 7-hydroxylase (Cyp2a5) genes in mouse liver is regulated by the PAR leucine zipper transcription factor DBP.	1999 Oct	10490589
Acute activation of Maxi-K channels (hSlo) by estradiol binding to the beta subunit.	1999 Sep 17	10489376
Involvement of cyclooxygenase 2 in the protective effect of 17beta-estradiol on hypercholesterolemic rabbit aorta.	2000 Aug 28	10964725
Molecular analysis of the inhibition of monocyte chemoattractant protein-1 gene expression by estrogens and xenoestrogens in MCF-7 cells.	2000 Jan	10614622
Intrinsic alcohol dehydrogenase and hydroxysteroid dehydrogenase activities of human mitochondrial short-chain L-3-hydroxyacyl-CoA dehydrogenase.	2000 Jan 1	10600649
Crosstalk between estrogen receptor alpha and the aryl hydrocarbon receptor in breast cancer cells involves unidirectional activation of proteasomes.	2000 Jul 28	10922479
Dramatic suppression of plasma and urinary prostate specific antigen and human glandular kallikrein by antiandrogens in male-to-female transsexuals.	2000 Mar	10687981
Changes in serum and tissue zinc levels in sex hormone-induced prostatic carcinogenesis in the noble rat.	2000 Nov-Dec	11006573
Relative binding affinity does not predict biological response to xenoestrogens in rat endometrial adenocarcinoma cells.	2000 Oct	11086226
Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta.	2000 Oct	11014220
Effects of arsenite on estrogen receptor-alpha expression and activity in MCF-7 breast cancer cells.	2000 Oct	11014213
Antiestrogenic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin in mouse uterus: critical role of the aryl hydrocarbon receptor in stromal tissue.	2000 Oct	11006360
Use of salivary biomarkers in biobehavioral research: cotton-based sample collection methods can interfere with salivary immunoassay results.	2001 Feb	11087962
Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells.	2001 Feb 2	11044445
Female steroid hormones modulate receptors for nerve growth factor in rat dorsal root ganglia.	2001 Jan	11133691
Metabolism of estradiol, ethynylestradiol, and moxestrol in rat uterus, vagina, and aorta: influence of sex steroid treatment.	2001 Jan	11124233
Stimulatory effect of clofibrate and gemfibrozil administration on the formation of fatty acid esters of estradiol by rat liver microsomes.	2001 Jan	11123380
Neuroprotection by estradiol.	2001 Jan	11040417
Affinity labeling of rat glutathione S-transferase isozyme 1-1 by 17beta -iodoacetoxy-estradiol-3-sulfate.	2001 Jan 19	11031273
Hormone binding by protein disulfide isomerase, a high capacity hormone reservoir of the endoplasmic reticulum.	2001 Jan 5	11035025
Acquisition of Lubrol insolubility, a common step for growth hormone and prolactin in the secretory pathway of neuroendocrine cells.	2001 Jan 5	11024038
In vivo regulation of syndecan-3 expression in the rat uterus by 17 beta-estradiol.	2001 Jan 5	11024013
Sulfonation of 17beta-estradiol and inhibition of sulfotransferase activity by polychlorobiphenylols and celecoxib in channel catfish, Ictalurus punctatus.	2007 Mar 10	17239972
Complex actions of estradiol-3-sulfate in late gestation fetal brain.	2011 Jul	21273638
[Study of gonadal hormone drugs in blocking filovirus entry of cells in vitro].	2015 Dec	27169275
Changes in Expression of Connexin Isoforms in the Caudal Epididymis of Adult Sprague-Dawley Rats exposed to Estradiol Benzoate or Flutamide at the Neonatal Age.	2016 Sep	27796005

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Estradiol-3-sulfate (E2SO4) infused intracerebroventricularly (icv) significantly increased plasma adrenocorticotropic hormone (ACTH) and cortisol concentrations. All minipumps in the treated fetuses were filled with E2SO4 in the vehicle (water) and minipumps in the control fetuses were filled with vehicle only. These minipumps deliver a constant infusion of 5 μL/h; the concentration of E2SO4 in infusates was therefore 8.33 μg/μL. It was concluded, that E2SO4 had complex actions on the fetal brain, which might involve deconjugation by steroid sulfatase. But that the net result of direct E2SO4 icv infusion was more complex than could be accounted for by infusion of E2 alone.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 13:04:37 GMT 2023` Edited by `admin` on `Sat Dec 16 13:04:37 GMT 2023`
Record UNII	37UIZ63WWM
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SODIUM ESTRADIOL

Common Name

English

Code System Code Type Description

CAS

15399-28-7

Created by admin on Sat Dec 16 13:04:37 GMT 2023 , Edited by admin on Sat Dec 16 13:04:37 GMT 2023

PRIMARY

FDA UNII

37UIZ63WWM

Created by admin on Sat Dec 16 13:04:37 GMT 2023 , Edited by admin on Sat Dec 16 13:04:37 GMT 2023

PRIMARY

PUBCHEM

145996636

Created by admin on Sat Dec 16 13:04:37 GMT 2023 , Edited by admin on Sat Dec 16 13:04:37 GMT 2023

PRIMARY

Related Record Type Details


					4TI98Z838E

ESTRADIOL

PARENT -> SALT/SOLVATE

Related Record Type Details


					4TI98Z838E

ESTRADIOL

ACTIVE MOIETY

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

Drug as perpetrator